2023 End-of-Year Review: CNS & Rare Disease Insights
)
‘Although it has definitely been a tricky and challenging year for neuroscience – and biopharma in general – there have been some amazing successes that are still worth celebrating.’
Working within the CNS & Rare Disease space for our Life Sciences team, Paula Doust Alba has had a busy year. In this video, she gives us her end-of-year review for 2023 – and while it hasn’t always been plain sailing, breakthroughs in Alzheimer’s have been particularly gratifying to note.
Check out this clip to hear Paula reflect on the demand for clinical talent and experienced CMOs, fundraising and development breakthroughs – in addition to her predictions for 2024!
Tags:
Cristian joined Venari Partners in 2019 and is a core member of the Life Sciences & Healthcare practice. He is hugely passionate about the Digital Health space, and the partner of choice to many emerging and high-growth HealthTech companies across the US & Europe. With over 6 years of experience headhunting global leaders within the Digital Health industry, Cristian helps organisations identify, attract, and retain the best Strategy, Business Development, Operations and Commercial talent around the world. Typical growth scenarios he supports include: - US GTM Expansion for European HealthTech companies - Commercial buildout, due to successful fundraising or product launch (US or EU) - CEO selection to replace a Founder who is looking to transition into a CTO/NED role. - Board level appointments Chairman, non-executive advisory etc. Retained executive recruitment is a core discipline, but the team is also equipped to provide expert Diversity, Equity, and Inclusion (DEI) mapping solutions, Interim & Consulting solutions, Board Advisory, Market Mapping, Compensation Benchmarking, and Leadership & Organisational Assessment. Outside of Venari Partners, as a former chef, he has a tremendous passion for food and loves to experiment with cooking and eating as many different cuisines as possible.
View Full Profile)
)
)
)
